盧修斯 司帕生坦 Sparsentan 線上購買
該藥物於2023年2月獲得美國FDA加速核准上市，針對內皮素A型受體(ETAR)和血管張力素II1型受體(AT1R)靶點，是一種處方藥，需謹遵醫囑。
查看商品
Opinion/decision on a Paediatric investigation plan (PIP): Filspari, sparsentan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Uro-nephrology, PIP number: EMA/PE/0000226166
Related medicine information Age appropriate oral liquid dosage formulation Email: huong.
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
文章相關商品
系統已根據文章標題、摘要和正文，自動匹配目前在售的強相關藥品。
常見問題
Which products are related to this article?
The system matched these relevant products from the article content: 盧修斯 司帕生坦 Sparsentan 線上購買.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
